登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、清算注销暨关联交易概述 金陵药业股份有限公司（以下简称"公司"）分别于2025年1月17日、2025年2月7日召开第九届董事会第 十五次会议和2025年第一次临时股东大会，审议通过了《关于南京新工医疗产业投资基金合伙企业（有 限合伙）拟清算注销暨关联交易的议案》，同意对南京新工医疗产业投资基金合伙企业（有限合伙） （以下简称"基金"）进行清算注销，并按基金合伙人实缴出资比例分配基金剩余财产。同时，股东大会 授权经理层办理与本次基金拟清算注销相关的具体事宜。具体内容详见公司于2025年1月21日在《中国 证券报》《证券时报》《上海证券报》和巨潮资讯网披露的《关于南京新工医疗产业投资基金合伙企业 （有限合伙）拟清算注销暨关联交易的公告》（公告编号：2025-007）。 二、清算注销进展情况 近日，基金取得了南京市雨花台区政务服务管理办公室出具的《登记通知书》（（320101142005）登字 〔2025〕第08140025号），准予基金进行注销登记。至此，基金清算 ...

Group 1 - The establishment of Linhai Zesheng Collaborative Life Health Venture Capital Partnership (Limited Partnership) with a capital contribution of 500 million yuan [1] - The business scope includes venture capital (limited to investments in unlisted companies), equity investment, and investment activities using self-owned funds [1] - The enterprise is co-funded by Hangzhou Mipeng Enterprise Management Partnership (Limited Partnership), which is under Baicheng Pharmaceutical (301096) [1]

Core Viewpoint - The article emphasizes the significance of the Singularity Program, highlighting its comprehensive approach to integrating medical knowledge, investment thinking, cutting-edge technology, and practical industry experience [3][6]. Group 1: Program Structure and Content - The program consists of 18 modules spread over 9 weekends, featuring immersive real-world visits [8][10]. - It covers various medical fields, including cardiovascular health, aesthetics, life sciences, weight management, and more, with a focus on both theoretical foundations and practical applications [14]. - Participants will engage in hands-on experiences, such as simulator operations and real project roadshows, to enhance their presentation and logical reasoning skills [11][13]. Group 2: Expert Involvement - The program is led by a team of senior mentors, including academic leaders, investment experts, technical specialists, and industry pioneers [4][7]. - Participants will have opportunities for one-on-one guidance from field experts and will engage in discussions with senior professionals from various sectors [12][19]. Group 3: Networking and Resources - The program facilitates connections with a global network of health industry innovators, providing priority access to research transformation projects and investment opportunities [12][19]. - It aims to create a comprehensive ecosystem covering the entire medical industry chain, enhancing collaboration among participants [9]. Group 4: Enrollment and Timeline - Enrollment for the program is open until June 30, 2025, with the course running from July to December 2025 [10][18]. - The program is hosted by the Global Health Industry Innovation Center, which focuses on bridging global medical innovation technologies and resources [18].

Core Viewpoint - Zhejiang University has played a significant role in China's higher education and has produced numerous successful entrepreneurs and investors, particularly in the field of technology and innovation [1][2]. Group 1: "Hangzhou Six Little Dragons" - The "Hangzhou Six Little Dragons" are notable for their focus on "hard technology," including artificial intelligence, robotics, and brain-computer interfaces, aiming to reshape industry logic and break technological barriers [2]. - Zhejiang University has been at the forefront of artificial intelligence since establishing its computer science department in 1978, becoming one of the first universities in China to offer an undergraduate program in AI in 2019 [2][3]. - Founders of several "Hangzhou Six Little Dragons" companies, such as DeepSeek and Cloud Deep Technology, are alumni of Zhejiang University, showcasing the university's influence on entrepreneurship [2][3]. Group 2: Alumni Achievements - As of May 17, 2024, 351 alumni from Zhejiang University hold key positions in 313 listed companies, indicating the university's strong entrepreneurial ecosystem [4][5]. - The "Future Entrepreneurs Cultivation Project," initiated in 1999, has produced 128 startups with a total market value exceeding 100 billion yuan, highlighting the university's commitment to fostering innovation [5]. - Zhejiang University's innovation culture emphasizes the integration of technological and industrial innovation, creating a vibrant ecosystem that supports startups at various growth stages [5]. Group 3: Notable Investors - Notable investors from Zhejiang University include Duan Yongping, known as the "father of industry" and "Chinese Buffett," who has made significant contributions to the tech industry and value investing [6][7]. - Duan Yongping has made substantial donations to Zhejiang University, supporting its development and infrastructure, reflecting his commitment to giving back to his alma mater [7]. - Other prominent investors include Chen Yuemeng, founder of Zhejiang Merchants Venture Capital, and Wang Huai, founder of Linear Capital, both of whom have made significant impacts in their respective fields [8][9][10].

Core Viewpoint - The article emphasizes the importance of efficiency over mere growth and scale in the current economic environment, advocating for a shift in focus towards efficiency as a primary metric for business success [3][4][10]. Group 1: Investment Philosophy - The founder of 嘉御资本, Wei Zhe, has led successful investments in various sectors, including new consumption, cross-border e-commerce, and technology, with a notable focus on efficiency as a key performance indicator [3][4]. - 嘉御资本 has invested in 14 leading companies in the overseas market, including Anker Innovations and Pop Mart, demonstrating a strong track record in identifying high-potential investments [3][4]. - The company plans to enter the medical sector, viewing it as an opportunity despite the current challenges in the industry, indicating a contrarian investment approach [3][4][27]. Group 2: Efficiency as a Key Metric - Wei Zhe argues that in the current "stock economy," efficiency should take precedence over growth and scale, as many companies fail not due to lack of funding but due to inefficiencies [9][10]. - The concept of "first efficiency indicators" is introduced, which should be personally monitored by founders, highlighting the critical role of efficiency in a company's DNA [11][12]. - The article discusses the need for companies to adapt to a new reality where efficiency is paramount, especially in a market where capital is becoming scarcer and more expensive [14][15]. Group 3: Insights on AIGC and Innovation - The emergence of AIGC (Artificial Intelligence Generated Content) is discussed, with a focus on the importance of affordability in technology adoption, as exemplified by DeepSeek's cost-effective solutions [16][17]. - Wei Zhe emphasizes that innovation should not come at the expense of efficiency, advocating for a balanced approach to technological advancements [16][17]. Group 4: Investment Success Stories - The article highlights the investment strategies behind successful companies like Anker Innovations and Pop Mart, focusing on their high product development success rates and global market aspirations [20][21][22]. - The efficiency in product development and market entry strategies of these companies is noted as a key factor in their success, showcasing the importance of strategic planning in investment decisions [20][21][22]. Group 5: Future Predictions - Wei Zhe shares three predictions regarding the future of technology and work, including a significant reduction in work hours due to AI advancements and a potential increase in human lifespan through medical innovations [33][34]. - The predictions reflect a belief in the transformative power of technology and its implications for business and society [33][34].

Group 1: Industry Trends - The Chinese healthcare market is undergoing significant changes, with the outpatient market gaining importance due to comprehensive medical reforms [1] - The balance between domestic and overseas markets is becoming crucial for companies, especially in light of trade events [1] - Technological advancements, particularly in AI represented by large models, are expected to create new market opportunities and transform production and treatment methods [1] Group 2: AI in Healthcare - AI is anticipated to bring profound changes to the healthcare sector, with applications expected to assist doctors in clinical documentation, diagnosis recommendations, and knowledge acquisition [1] - AI will also serve as a health assistant for individuals, providing comprehensive services throughout the healthcare process [1] - Data privacy and security issues related to healthcare data must be addressed to ensure fairness and compliance in AI applications [1] Group 3: Investment Opportunities - The investment landscape is shifting, with a focus on "niche" opportunities rather than disruptive innovations, emphasizing the importance of strategic investments [2] - The current investment environment is challenging, but there are opportunities arising from the revaluation of Chinese tech assets and improving market conditions in Hong Kong [3] - Companies are encouraged to diversify markets and explore opportunities in regions like the Middle East and Southeast Asia, as well as capitalize on domestic substitution and supply chain localization [3] Group 4: Market Performance and Reports - The "2025 Future Medical 100 Companies Growth Report" indicates that the Yangtze River Delta region has the highest number of listed companies, with Shanghai leading [4] - The report highlights that innovative medical devices and smart manufacturing are gaining traction, with a notable increase in valuations despite a challenging investment climate [4] - The innovative drug development sector is experiencing a cooling effect from the capital market, but upstream supply chain projects still present relatively low investment risks and substantial market potential [4]

Core Viewpoint - Kangqiao Capital has emerged as a significant player in the healthcare investment sector, managing 65 billion and recently launching a 7 billion RMB healthcare M&A fund, the largest of its kind in China [2][3]. Fund Overview - The newly established fund has a target size of 10 billion RMB and focuses on sectors such as biomedicine, medical devices, consumer healthcare, and healthcare services [3][4]. - Major initial investors include Beijing Guoguan and Beijing Yizhuang International Biomedical Investment Management, with potential for further investment from insurance capital [3]. Investment Strategy - Kangqiao Capital employs a unique "investor-operator" model, leveraging its global perspective in healthcare M&A and collaborating with state-owned assets for resource integration and policy support [4]. - The firm has successfully raised over 9 billion USD in the healthcare sector, demonstrating a strategic shift towards M&A during a time when many are focused on large-scale investments [4][12]. Notable Case Studies - The case of Yunding Xinyao illustrates Kangqiao's approach, where it played a pivotal role in securing a 835 million USD license-in deal, leading to a successful IPO with a market cap exceeding 20 billion HKD [7][8]. - Kangqiao's strategic decisions, such as divesting non-profitable segments during market downturns, have proven effective in maintaining company value and facilitating growth [8][9]. International Expansion - Kangqiao's acquisition of Hugel, a leading Korean medical aesthetics company, marks its largest overseas deal, enhancing its global footprint and operational capabilities [14][15]. - The firm aims to assist regional companies in achieving global expansion, utilizing its diverse talent pool and operational expertise [17]. Market Position - Kangqiao Capital's model challenges the traditional landscape of M&A in China, positioning itself as a comprehensive solution provider in the healthcare investment space [18].